05), except for visualization around the acetabular component. Abnormal imaging findings were seen in 25 hips, and either equally visible or visible but less conspicuous on RPCA MAVRIC-SL in 21 out of 25 cases. In 4 cases, a small joint effusion was queried on MAVRIC-SL but not RPCA MAVRIC-SL, but the presence or absence of a small effusion did not affect subsequent clinical management and patient outcome. While the overall image quality is reduced, RPCA MAVRIC-SL allows for significantly reduced scan time and maintains almost equal diagnostic performance. While the overall image quality is reduced, RPCA MAVRIC-SL allows for significantly reduced scan time and maintains almost equal diagnostic performance. Patients with type 1 diabetes mellitus (T1DM) receiving insulin therapy commonly suffer from insulin-mediated hypoglycemia and require glucagon for glycemic control to achieve normal plasma glucose (PG) levels. Severe hypoglycemia will endanger the life of patients and require intervention. Stable glucagon analog dasiglucagon was approved for the treatment of patients with severe hypoglycemia and is administered via Zegalogue autoinjector/Zegalogue prefilled syringe.The main purpose of this review article is to review the basic properties and clinical effects of dasiglucagon. We search related literature on CNKI, Web of Science and PubMed by keywords dasiglucagon, hypoglycemia, type 1 diabetes, glucagon. Carry out a careful review of the included literature. Dasiglucagon information on clinicaltrials.gov and https//www.fda.gov/ has been adopted. Dasiglucagon is a novel peptide analog of human glucagon, which can effectively rescue insulin-induced severe hypoglycemia in patients with T1DM and rapidly inc has been proven that dasiglucagon has definite stability and solubility in aqueous formulations. Dasiglucagon has a higher absorption rate and longer plasma elimination half-life than traditional reconstituted glucagon. In three randomized, double-blind, placebo-controlled trials in children aged 6 to 17 years and adults with T1DM the median time to glycemic recovery in 10 min after dasiglucagon administration was significantly faster than placebo and 99% of patients recovered within 15 min after subcutaneous injection of dasiglucagon in the key phase 3 clinical trial. The most common adverse reactions in these phase 3 trials were vomiting, nausea, diarrhea, headache, and injection site pain. Tumors of the testes not originating from germinal epithelium are arare entity and represent adiagnostic and therapeutic challenge. Leydig cell tumors (LCT) are rare stromal tumors of the testis. To present current approaches in diagnostic and treatment of LCT. A literature search in PubMed was performed and the currently available guidelines concerning LCT were evaluated. Articles and book chapters were selected based on relevance to daily practice. The low incidence of Leydig cell tumors not originating from the germinal epithelium, but from the stroma of the testis requires astandardized approach to determine relevant differential diagnosis and to optimize diagnosis and treatment depending on the current standard of knowledge and to determine whether it is benign or malignant. While more than 90% of LCT are benign and treatment is only restricted to the testis, malignant subtypes require radical surgical resection of the testicular and metastatic sites. Astandardized diagnostic and therapeutic approach as well as aprospective registry of rare LCT could facilitate further detailed analysis to improve the understanding of tumor biology resulting in optimized therapeutic guidelines including follow-up strategies. A standardized diagnostic and therapeutic approach as well as a prospective registry of rare LCT could facilitate further detailed analysis to improve the understanding of tumor biology resulting in optimized therapeutic guidelines including follow-up strategies. In 2008, statutory skin cancer screening (sSCS) was introduced in Germany for people aged ≥ 35years with statutory health insurance (SHI). The aim is to diagnose malignant skin lesions at an early stage, reduce mortality and improve morbidity and quality of life. Although sSCS was introduced more than adecade ago, only apart of the public is aware of it. What are the reasons for the low participation rate in sSCS in the eligible population? In computer-assisted phone interviews with arepresentative population sample of N = 1015 persons aged ≥ 18years with SHI attitude towards skin cancer, rate of use of sSCS and reasons for nonparticipation were surveyed in January 2019. Parts of the data were compared with previous surveys from 2011, 2013 and 2015. Among the 1015 participants 40% were concerned about skin cancer (2011 45%; 2013 51%; 2015 46%). Of the respondents 75.4% were authorised to use sSCS. Of these 52.6% had never participated in sSCS before. However, participation increased with age. Further, the nonparticipation rate for those with ahigh school-leaving certificate (45%) was significantly lower than for those with alower schooling level (58%). The option for sSCS was unknown to 35% of nonparticipants. As areason for nonparticipation 20% mentioned alack of time, while 58% saw no need for it because they felt healthy. In general, 91% of all respondents considered early preventive examinations to be useful and 66% had already taken part in other preventive examinations. The low participation rate of about 50% in sSCS and the decreasing concern about skin cancer suggest that further education of the general population about the relevance of skin cancer with a focus on risk groups is necessary. The low participation rate of about 50% in sSCS and the decreasing concern about skin cancer suggest that further education of the general population about the relevance of skin cancer with a focus on risk groups is necessary.Hidradenitis suppurativa/acne inversa (HS) is associated with numerous and relevant restrictions on the quality of life for those affected and their relatives. https://www.selleckchem.com/products/BMS-536924.html The exact prevalence of HS varies significantly across studies, but it is likely to be higher than suggested in previous publications. HS care is associated with high costs for the healthcare system and for those affected. The introduction of biologic therapy has led to additional costs, but also to considerable additional benefits in terms of care. In view of the complexity of diagnostics and therapy, there is a particular need for optimized care concepts in order to reduce the burden on those affected, their relatives and the healthcare system.